Intera Oncology

Clinical Evidence For HAI Therapy for Intrahepatic Cholangiocarcinoma

HAI Therapy for IHCC

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma A Phase 2 Clinical Trial (JAMA Oncol. – Oct, 2019)

Andrea Cercek, Thomas Boerner, Benjamin R Tan, Joanne F Chou, Mithat Gönen, Taryn M Boucher, Haley F Hauser, Richard K G Do, Maeve A Lowery, James J Harding, Anna M Varghese, Diane Reidy-Lagunes, Leonard Saltz, Nikolaus Schultz, T Peter Kingham, Michael I D'Angelica, Ronald P DeMatteo, Jeffrey A Drebin, Peter J Allen, Vinod P Balachandran, Kian-Huat Lim, Francisco Sanchez-Vega, Neeta Vachharajani, Maria B Majella Doyle, Ryan C Fields, William G Hawkins, Steven M Strasberg, William C Chapman, Luis A Diaz Jr, Nancy E Kemeny, William R Jarnagin

In this single arm, prospective, Phase II clinical trial, unresectable patients with no distant metastases treated with HAI therapy along with systemic chemotherapy reached median overall survival of 25.0 months and the 1-year OS rate of 89.5%.

Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis (Annals of Surgical Oncology - 2022)

Jessica J. Holster BSc, Marouan El Hassnaoui BSc, Stijn Franssen MD, Jan N. M. IJzermans MD, PhD, Jeroen de Jonge MD, PhD, Bianca Mostert MD, PhD, Wojciech G. Polak MD, PhD, Roeland F. de Wilde MD, PhD, Marjolein Y. V. Homs MD, PhD & Bas Groot Koerkamp MD, PhD

This systematic review of nine publications with 154 unique patients demonstrated HAI was associated with substantial improvement in survival for iCCA patients.
Patients with unresectable iCCA receiving HAI in addition to systemic chemotherapy had a 39.5% 3-year OS, while no survivors were reported in the ABC trials, in which only systemic chemotherapy was used.